Details of the Drug

General Information of Drug (ID: DM0AUCH)

Drug Name
Reslizumab
Indication
Disease Entry ICD 11 Status REF
Severe asthma CA23 Approved [1]
Eosinophilic asthma CB02.0 Phase 3 [2]
Asthma CA23 Phase 2 [3]
Drug Type
Monoclonal antibody
ADMET Property
Clearance
The clearance of drug is 7 mL/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 24 days []
Vd
The volume of distribution (Vd) of drug is 5 L []
Cross-matching ID
DrugBank ID
DB06602
TTD ID
D0O8KX
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-5 (IL5) TTPREZD IL5_HUMAN Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Nasal and bronchial airway
The Studied Disease Asthma [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-5 (IL5) DTT IL5 4.22E-01 -0.01 -0.04
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8091).
3 ClinicalTrials.gov (NCT00587288) Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
4 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.